坎地沙坦酯对高血压脑梗死患者C反应蛋白水平的影响的研究.docVIP

坎地沙坦酯对高血压脑梗死患者C反应蛋白水平的影响的研究 　　[摘要] 目的:研究坎地沙坦酯对高血压脑梗死患者C-反应蛋白(C reactive protein,CRP)水平的影响。方法:选取高血压脑梗死患者160例,随机分为常规治疗组和坎地沙坦酯治疗组。常规治疗组(n=80)采用急性脑梗死常规治疗,如病情稳定后血压仍控制不理想,加用血管紧张素Ⅱ受体拮抗剂以外的降压药物,坎地沙坦酯治疗组(n=80)在常规治疗基础上病情稳定后血压仍明显偏高,给予坎地沙坦酯4～8 mg口服,1次/d,8周为1个疗程,观察入院时、坎地沙坦酯治疗1、8周后CRP水平的变化。结果:脑梗死组患者CRP水平明显高于正常对照组(P0.01),常规治疗组和坎地沙坦酯治疗组治疗1周后,上述指标与治疗前相比均有下降(P0.05),治疗8周后坎地沙坦酯组改变更加显著(P0.01),两组血压均控制稳定。结论:用坎地沙坦酯治疗后,高血压脑梗死患者C-反应蛋白水平明显降低,血压控制稳定,坎地沙坦酯能够调控血压,同时可降低脑梗死患者C-反应蛋白水平,预防脑梗死复发,从而减少高血压脑梗死的不良预后。 　　[关键词] 坎地沙坦酯;脑梗死;C-反应蛋白 　　[中图分类号] R544.1 [文献标识码]A [文章编号]1673-7210(2010)06(a)-025-02 　　 　　Study on the effects of Candesartan Cilexetil on high blood pressure cerebral infarct patients C reactive protein level 　　DU Fengqi, DENG Qiwu, XU Shan 　　(Department of Neurology, the First Peoples Hospital of Haizhu District, Guangzhou City, Guangzhou 510220, China) 　　[Abstract] Objective: To study the effect of Candesartan Cilexetil on the C reactive protein (CRP) level of high blood pressure cerebral infarct patients. Methods: 160 cases of high blood pressure cerebral infarct patients were treated randomly with routine therapy (n=80) and Candesartan Cilexetil (n=80). Routine group was treated with conventional therapy of acute cerebral infarction and taking antihypertensive drug rather than angiotensin Ⅱ receptor antagonist if illness was stable but blood pressure remained unsatisfactory. Candesartan Cilexetil group was treated with oral Candesartan Cilexetil 4-8 mg once a day, and 8 weeks was a treatment course after conventional therapy. The CRP level changes of admission 1 week therapy and 8 weeks therapy was observed. Results: CRP levels of cerebral infarction group were significantly higher than the control group (P0.01), CRP of routine treatment group and the Candesartan Cilexetil treatment group decreased significantly (P0.05) after 1 week, Candesartan Cilexetil group changed more significant than routine group (P0.01), and blood pressure kept stable. Conclusion: After Candesartan Cilex